BR112016022407A2 - composições e métodos relacionados ao diagnóstico do câncer de próstata - Google Patents

composições e métodos relacionados ao diagnóstico do câncer de próstata

Info

Publication number
BR112016022407A2
BR112016022407A2 BR112016022407A BR112016022407A BR112016022407A2 BR 112016022407 A2 BR112016022407 A2 BR 112016022407A2 BR 112016022407 A BR112016022407 A BR 112016022407A BR 112016022407 A BR112016022407 A BR 112016022407A BR 112016022407 A2 BR112016022407 A2 BR 112016022407A2
Authority
BR
Brazil
Prior art keywords
prostate cancer
compositions
cancer diagnosis
methods related
aspects
Prior art date
Application number
BR112016022407A
Other languages
English (en)
Inventor
j vickers Andrew
Steinmiller David
Lilja Hans
Pettersson Kim
T Scardino Peter
Lovgren Timo
Linder Vincent
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of BR112016022407A2 publication Critical patent/BR112016022407A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)

Abstract

a presente invenção refere-se os aspectos da descrição relacionados aos métodos melhorados para a previsão de se uma biópsia do tecido da próstata obtida a partir de um indivíduo conterá câncer de próstata detectável.
BR112016022407A 2014-03-28 2015-03-27 composições e métodos relacionados ao diagnóstico do câncer de próstata BR112016022407A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461972099P 2014-03-28 2014-03-28
PCT/US2015/023096 WO2015148979A1 (en) 2014-03-28 2015-03-27 Compositons and methods related to diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
BR112016022407A2 true BR112016022407A2 (pt) 2017-12-12

Family

ID=54196462

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016022407A BR112016022407A2 (pt) 2014-03-28 2015-03-27 composições e métodos relacionados ao diagnóstico do câncer de próstata

Country Status (25)

Country Link
US (2) US11761962B2 (pt)
EP (2) EP3299977A1 (pt)
JP (3) JP6775488B2 (pt)
KR (1) KR102505543B1 (pt)
CN (2) CN114740202A (pt)
AR (1) AR099883A1 (pt)
AU (1) AU2015237270B2 (pt)
BR (1) BR112016022407A2 (pt)
CA (1) CA2944001C (pt)
CL (1) CL2016002419A1 (pt)
DE (1) DE202015009668U1 (pt)
DK (1) DK3123381T3 (pt)
EA (1) EA201691952A1 (pt)
ES (1) ES2964706T3 (pt)
FI (1) FI3123381T3 (pt)
HU (1) HUE065029T2 (pt)
IL (2) IL247981B (pt)
MX (2) MX2016012667A (pt)
MY (1) MY192513A (pt)
PE (1) PE20170298A1 (pt)
PL (1) PL3123381T3 (pt)
PT (1) PT3123381T (pt)
SG (2) SG11201608035UA (pt)
TW (1) TWI687688B (pt)
WO (1) WO2015148979A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5305361B2 (ja) 2007-05-04 2013-10-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニー 流体コネクタおよびマイクロ流体システム
ES2812260T3 (es) 2009-02-02 2021-03-16 Opko Diagnostics Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
EP2823427B1 (en) 2012-03-05 2020-12-16 OY Arctic Partners AB Computer systems, methods and computer readable storage medium for predicting risk of prostate gland volume
DK3253800T3 (da) 2015-03-27 2021-05-31 Opko Diagnostics Llc Prostata antigen standarder og bruge deraf
EP3922265A1 (en) 2015-10-05 2021-12-15 Fredax AB Humanized anti psa (5a10) antibodies
US10852310B2 (en) 2015-12-11 2020-12-01 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
HUE055156T2 (hu) 2015-12-29 2021-11-29 Opko Diagnostics Llc Folyadékgyûjtési eszköz és kapcsolódó módszerek
US20190355473A1 (en) * 2017-01-08 2019-11-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Systems and methods for using supervised learning to predict subject-specific pneumonia outcomes
KR102052398B1 (ko) 2018-04-18 2019-12-05 (주)유로테크 전립선암 진단용 바이오마커 및 이의 용도
WO2020205204A1 (en) 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
KR20240022906A (ko) * 2022-08-12 2024-02-20 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
EP0725593B1 (en) 1993-10-28 2004-04-07 I-Stat Corporation Fluid sample collection and introduction device
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
AU6788796A (en) 1995-08-03 1997-03-05 Akzo Nobel N.V. Diagnostic device
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
JP4495349B2 (ja) 1999-01-28 2010-07-07 ジェン−プローブ・インコーポレーテッド 癌の遺伝マーカーを生物学的サンプルにおいて検出するための核酸配列
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
WO2002030562A1 (en) 2000-10-10 2002-04-18 Aviva Biosciences Corporation An integrated biochip system for sample preparation and analysis
AU4322102A (en) 2000-11-20 2002-06-18 Eastern Virginia Med School Methods and devices for the quantitative detection of prostate specific membraneantigen and other prostatic markers
AU2002362447A1 (en) 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
CA2468674A1 (en) 2001-12-05 2003-06-12 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
JPWO2003100425A1 (ja) 2002-05-28 2005-11-04 株式会社常光 免疫学的クロマトグラフ法の試験紙片の読み取り定量装置
CN103969449B (zh) 2002-08-06 2016-11-23 约翰霍普金斯大学 用于检测卵巢癌的生物标记的用途
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
EP1592809B1 (en) 2003-02-07 2013-04-10 Diagnocure Inc. Method to detect prostate cancer in a sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
EP1535667A1 (en) 2003-11-28 2005-06-01 Sysmex Corporation Analyzer, assay cartridge and analyzing method
WO2005056186A1 (en) 2003-12-10 2005-06-23 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A modular biochip assembly
EP1704405A1 (en) 2003-12-31 2006-09-27 The President and Fellows of Harvard College Assay device and method
PL1776181T3 (pl) 2004-01-26 2014-03-31 Harvard College Układ i sposób doprowadzania płynów
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
WO2005111625A2 (en) 2004-05-11 2005-11-24 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
JP2008508538A (ja) 2004-08-02 2008-03-21 チルドレンズ・メディカル・センター・コーポレイション 癌についての血小板生物マーカー
CN101087889A (zh) 2004-09-17 2007-12-12 约翰·霍普金斯大学 乳癌的生物标记
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122311A2 (en) 2005-05-11 2006-11-16 The Trustees Of The University Of Pennsylvania Microfluidic chip
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
KR20090006837A (ko) 2006-03-24 2009-01-15 페노미넘 디스커버리스 인코포레이티드 전립선 암 진단용 생물표지자 및 그의 제조방법
CN101506376A (zh) 2006-07-03 2009-08-12 埃克森希特医疗股份有限公司 ***特异性转录物及其在***癌治疗和诊断中的应用
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
ES2560868T3 (es) 2006-12-22 2016-02-23 Phadia Ab Alérgeno de calicreína de próstata novedoso
JP5305361B2 (ja) 2007-05-04 2013-10-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニー 流体コネクタおよびマイクロ流体システム
WO2008140774A2 (en) 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断***癌试剂盒及其制备方法和检测方法
US20090087860A1 (en) 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离***特异性抗原化学发光免疫分析测定试剂盒及其制备方法
CN101861522B (zh) 2007-10-22 2014-05-14 圣文森特医院悉尼有限公司 预后方法
WO2009085196A1 (en) 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
EP2281201B1 (en) 2008-05-14 2018-03-28 ETH Zurich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
JP5393798B2 (ja) 2008-10-20 2014-01-22 リポサイエンス，インコーポレイテッド リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム
US20110236903A1 (en) 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
EP2376226B1 (en) 2008-12-18 2018-09-12 Opko Diagnostics, LLC Improved reagent storage in microfluidic systems and related articles and methods
WO2010075446A1 (en) 2008-12-23 2010-07-01 Soar Biodynamics, Ltd. Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
ES2812260T3 (es) 2009-02-02 2021-03-16 Opko Diagnostics Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
NZ596054A (en) 2009-05-01 2013-07-26 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
JP5933432B2 (ja) 2009-06-04 2016-06-08 メタノミクス ヘルス ゲーエムベーハー 前立腺癌を診断する手段と方法
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) * 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
CN102844332B (zh) * 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
PE20130803A1 (es) 2010-04-16 2013-07-10 Opko Diagnostics Llc Sistema y dispositivos para analisis de muestra
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
WO2012129408A2 (en) 2011-03-22 2012-09-27 The Johns Hopkins University Biomarkers for aggressive prostate cancer
WO2012170776A2 (en) 2011-06-09 2012-12-13 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
CN103688166B (zh) 2011-07-21 2016-12-07 和光纯药工业株式会社 血浆中氨基酸分析用标准液
EP2771037B1 (en) 2011-10-28 2016-08-03 Fredax AB Therapeutic agents and uses thereof
US20150044666A1 (en) 2012-01-13 2015-02-12 Iris International Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
EP2823427B1 (en) 2012-03-05 2020-12-16 OY Arctic Partners AB Computer systems, methods and computer readable storage medium for predicting risk of prostate gland volume
WO2013172779A2 (en) * 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer
KR20150023904A (ko) 2012-06-27 2015-03-05 버그 엘엘씨 전립선암의 진단 및 치료에서의 마커의 용도
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种***特异性抗原检测试剂盒及其制备方法
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
EP2922970B1 (en) 2012-11-20 2018-08-08 Phadia AB Prognostic method for individuals with prostate cancer
MY182773A (en) 2012-11-20 2021-02-05 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
HUE043875T2 (hu) 2013-11-19 2019-09-30 Fredax Ab Humanizált, kallikrein-2 elleni antitest
CA2940445C (en) 2014-03-11 2021-11-30 Phadia Ab Method for detecting a solid tumor cancer
US20170089904A1 (en) 2014-03-28 2017-03-30 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3268978A1 (en) 2015-03-12 2018-01-17 Thermo Finnigan LLC Methods for data-dependent mass spectrometry of mixed biomolecular analytes
DK3253800T3 (da) 2015-03-27 2021-05-31 Opko Diagnostics Llc Prostata antigen standarder og bruge deraf
BR112017022391A2 (pt) 2015-04-29 2018-07-10 Opko Diagnostics Llc composições e métodos para a fiscalização de câncer de próstata
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
US20210208146A1 (en) 2018-05-16 2021-07-08 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Also Published As

Publication number Publication date
TWI687688B (zh) 2020-03-11
AR099883A1 (es) 2016-08-24
IL247981A0 (en) 2016-11-30
MX2016012667A (es) 2017-01-09
SG10201808585TA (en) 2018-11-29
IL247981B (en) 2021-02-28
AU2015237270B2 (en) 2021-09-09
SG11201608035UA (en) 2016-10-28
US11761962B2 (en) 2023-09-19
ES2964706T3 (es) 2024-04-09
AU2015237270A1 (en) 2016-10-20
EP3123381A4 (en) 2018-02-21
DE202015009668U1 (de) 2019-01-21
US20160025732A1 (en) 2016-01-28
IL280039A (en) 2021-03-01
JP7506131B2 (ja) 2024-06-25
EP3299977A1 (en) 2018-03-28
EP3123381A1 (en) 2017-02-01
MY192513A (en) 2022-08-24
MX2022002365A (es) 2022-04-06
EP3123381B1 (en) 2023-10-11
KR102505543B1 (ko) 2023-03-02
FI3123381T3 (fi) 2023-11-27
CA2944001A1 (en) 2015-10-01
CA2944001C (en) 2023-08-15
PE20170298A1 (es) 2017-04-18
TW201621320A (zh) 2016-06-16
HUE065029T2 (hu) 2024-04-28
DK3123381T3 (da) 2023-11-27
CN106663149A (zh) 2017-05-10
PT3123381T (pt) 2023-12-22
JP7256781B2 (ja) 2023-04-12
CN114740202A (zh) 2022-07-12
CL2016002419A1 (es) 2017-03-31
JP2021009157A (ja) 2021-01-28
JP2017515127A (ja) 2017-06-08
WO2015148979A8 (en) 2016-01-07
PL3123381T3 (pl) 2024-02-26
JP2023017841A (ja) 2023-02-07
IL280039B (en) 2021-12-01
US20230393137A1 (en) 2023-12-07
KR20170008729A (ko) 2017-01-24
WO2015148979A1 (en) 2015-10-01
EA201691952A1 (ru) 2017-05-31
JP6775488B2 (ja) 2020-10-28

Similar Documents

Publication Publication Date Title
BR112016022407A2 (pt) composições e métodos relacionados ao diagnóstico do câncer de próstata
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
IL246917B (en) Biomarker and early diagnosis methods for Alzheimer's disease
EP3307243A4 (en) Diagnostic test for early stage cancer
TN2017000242A1 (en) Compositions and methods for antibodies targeting bmp6
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
EP3140426A4 (en) Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
EP3227686A4 (en) Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
HK1224370A1 (zh) 用於肝癌的無創診斷的特異性生物標誌物組
BR112017006593A2 (pt) método para detectar câncer de ovário
BR112015022162A2 (pt) sonda fluorescente de zinco
MA40636A (fr) Procédés pour détecter le cancer de la prostate
DK3580567T3 (da) I vitro-fremgangsmåde til diagnose af lungkræft
EP3092027A4 (en) Transpapillary methods and compositions for diagnosing and treating breast conditions
EP3389023A4 (en) ONOMATOPE PRESENTATION DEVICE CORRESPONDING TO EVALUATION RESULTS OF AN ENVIRONMENT NEARBY
BR112016028948A2 (pt) ?composição bifásica?
EP3679061A4 (en) EARLY PROGNOSIS OF BREAST LESIONS
EP3358352A4 (en) Method for estimating pathological tissue diagnosis result (gleason score) of prostate cancer
EP3189332A4 (en) Biomarkers for detection of breast cancer
BR112016028909A2 (pt) método e dispositivo para fechamento de tecidos
EP3387443A4 (en) INTEGRATED ANALYSIS TO DETERMINE PROGNOSIS AFTER THE TREATMENT OF PRIMARY BREAST CANCER
BR112017011303A2 (pt) métodos de preparação de tecidos embriogênicos para transformação de cana-de-açúcar
EP3397259A4 (en) COMPOSITIONS AND METHODS FOR SCREENING AND DIAGNOSIS OF PROSTATE CANCER
IES20140280A2 (en) Human targets II

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]